Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Cannara Biotech ( (TSE:LOVE) ) just unveiled an update.
Cannara Biotech Inc. reported record financial results for the first quarter of 2025, achieving a 29% increase in net revenues to $25.1 million and a Canadian market share of 4.1%, a 28% increase quarter over quarter. The company demonstrated robust profitability with a gross profit margin of 39% and achieved record-high adjusted EBITDA, operating cash flow, and free cash flow. Cannara plans to further expand by activating two additional grow zones and launching over 20 new products in 2025, strengthening its leadership in the Canadian cannabis market.
More about Cannara Biotech
Cannara Biotech Inc. is a vertically integrated producer of premium-grade cannabis and derivative products, operating two large facilities in Québec. The company focuses on delivering affordable, high-quality cannabis products and has established a significant presence in the Canadian market.
YTD Price Performance: 11.32%
Average Trading Volume: 16,630
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $53.19M
See more insights into LOVE stock on TipRanks’ Stock Analysis page.
